TransCode Therapeutics Advances RNA Oncology Pipeline Targeting Metastatic Cancer with Novel Delivery Platform
核心洞察
TransCode Therapeutics is developing RNA-based therapies for metastatic cancer (搜索), with lead candidate TTX-MC138 targeting microRNA-10b using a proprietary iron oxide nanoparticle delivery system.
The global metastatic cancer (搜索) treatment market was estimated at $116.1 billion in 2024 and is projected to reach $168.0 billion by 2029, growing at a CAGR of 7.7%.
The company's platform includes TTX-RIGA for immune stimulation, TTX-CRISPR for gene editing, and TTX-mRNA for cancer vaccines, alongside siRNA candidates TTX-siPDL1 and TTX-siLIN28B.
TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage biopharmaceutical company, is advancing a pipeline of RNA-based oncology therapeutics designed to target metastatic disease—the stage of cancer responsible for the vast majority of cancer-related mortality. The company's lead candidate, TTX-MC138, is an antisense oligonucleotide/antagomir that functionally operates through microRNA (miRNA) inhibition, targeting miR-10b (搜索) in established metastases.
The global market for cancer therapeutics with an emphasis on recurrent and metastatic disease was estimated at $116.1 billion in 2024 and is projected to grow to $168.0 billion by 2029, reflecting a compound annual growth rate (CAGR) of 7.7%. Individual metastatic indications underscore the scale of unmet need: the metastatic breast cancer therapeutics market alone is projected to grow from $21.80 billion in 2024 to $51.22 billion by 2032, while the metastatic non-small cell lung cancer market was valued at $18.50 billion in 2025.
RNA Oncology: Targeting the Instruction Layer
RNA oncology represents a paradigm shift from traditional approaches that target DNA or proteins. Instead, RNA-based therapies intervene at the messenger layer that translates genetic code into proteins. As noted in the Zacks Small Cap Research analysis, "RNA is the messenger that translates genetic code into proteins. Traditional oncology often targets DNA or proteins, while RNA oncology targets the instruction layer in between."
Therapeutic RNA operates through several distinct mechanisms. mRNA vaccines—similar to the technology used in Pfizer's and Moderna's COVID-19 vaccines—instruct the immune system to recognize tumor-specific neoantigens. RNA interference (RNAi) employs small RNA molecules such as siRNA to silence specific genes that cancer cells depend on for survival or chemotherapy resistance. Antisense oligonucleotides (ASOs) are synthetic, single-stranded RNA or DNA strings that bind to target mRNA, physically blocking translation of harmful proteins or triggering degradation of the target.
TransCode's TTX-MC138 bridges the ASO and miRNA therapeutic categories: it is technically delivered as an ASO/antagomir but functionally operates through miRNA inhibition. The target, microRNA-10b, was identified by TransCode co-founder and Chief Scientific Officer Dr. Zdravka Medarova as a therapeutic target in established metastases.
The miRNA Regulatory Network
MicroRNAs are short, 19–24 nucleotide, non-coding RNAs that function as master regulators of the genome. Unlike siRNA, which typically corresponds to a single gene, a single miRNA can regulate hundreds of genes simultaneously. "miRNAs require only partial complementarity to recognize their targets and can bind to many different mRNAs with varying levels of affinity," the research note explains.
In cancer, miRNAs play a dual role. Oncogenic miRNAs such as miR-155 (搜索) and miR-21 (搜索) are frequently upregulated across multiple cancer types, driving uncontrolled cell growth. Conversely, tumor-suppressor miRNAs like miR-15a/16-1 can be lost during malignant transformation. Anti-miRNA oligonucleotides—synthetic molecules designed to inhibit oncogenic miRNAs—bind to their target and sequester it, preventing interaction with complementary mRNAs.
The pleiotropic nature of miRNAs also presents complexity. A 2013 study by Dudda et al. demonstrated that the absence of miR-155 (搜索) impaired the accumulation of effector CD8⁺ T cells, resulting in diminished anti-tumor immune responses—illustrating that the same miRNA can have both oncogenic and immune-protective functions.
Solving the Extrahepatic Delivery Challenge
One of the most significant barriers in RNA therapeutics has been delivery beyond the liver. Common non-viral carriers such as lipid nanoparticles and GalNAc conjugates exhibit strong hepatic tropism, making targeting of the central nervous system, lungs, and tumors inefficient. "Many miRNA candidates have stalled in trials due to insufficient extrahepatic efficacy, even when using advanced carriers," according to the Zacks analysis.
Tumors present additional obstacles: a dense extracellular matrix, stromal barriers, high interstitial fluid pressure, and convoluted vasculature all impede drug penetration. TransCode's solution employs an iron oxide nanoparticle core optimized to carry various nucleic acid payloads. The iron oxide core avoids ApoE-mediated hepatocyte uptake, while the nanoparticle's dextran coating attracts tumors to its sugars, promoting rapid, preferential internalization by malignant cells while sparing normal tissue.
Once inside the cell, a disulfide linker cleaves, releasing the miRNA inhibitor. The oligonucleotide then binds to miR-10b (搜索) and silences the RNA molecule. This approach enables systemic delivery of nucleic acids to tumors and metastases outside the liver.
Pipeline and Platform Technologies
Beyond TTX-MC138, TransCode is advancing additional preclinical programs. TTX-siPDL1 and TTX-siLIN28B are siRNA-based therapies designed to modulate key proteins involved in cancer progression. The company is also developing a suite of "cancer agnostic" technology platforms: TTX-RIGA, an RNA-based approach to stimulate immune responses within tumors; TTX-CRISPR, a gene-editing platform for repairing or eliminating cancer-causing genes; and TTX-mRNA, an mRNA-based platform for creating cancer vaccines designed to activate the immune system against tumor cells.
The leadership team combines extensive industry experience. Dr. Philippe P. Calais, CEO and Executive Chairman, brings over 23 years of experience across public and private biotechnology companies. Dr. Zdravka Medarova, CSO and co-founder, developed the company's core nanodelivery platform. Thomas A. Fitzgerald, CFO, has been with the company since 2018 and previously served as interim CEO.
Market Opportunity and Future Directions
The addressable markets for TransCode's pipeline are substantial. The metastatic breast cancer treatment market was valued at $17.13 billion in 2021 and is anticipated to reach $41.74 billion by 2030, growing at a CAGR of 10.4%. The metastatic melanoma therapeutics market is estimated at $8.00 billion in 2025 and expected to reach $18.02 billion by 2032, exhibiting a CAGR of 12.3%. The metastatic colorectal cancer market is projected to grow from $6.78 billion in 2024 to $19.06 billion by 2035.
As RNA therapeutics continue to mature, the ability to target previously undruggable proteins and rapidly design therapies based on tumor genetic sequences positions this modality as a potentially transformative approach in oncology. TransCode's focus on overcoming the extrahepatic delivery barrier may prove critical in unlocking the full therapeutic potential of RNA-based cancer treatments.